These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 16625522

  • 1. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
    Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O.
    Hum Psychopharmacol; 2006 Apr; 21(3):139-49. PubMed ID: 16625522
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
    Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E.
    J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P, Touchon J, Billardon M.
    Encephale; 1997 Dec; 23(4):290-9. PubMed ID: 9417395
    [Abstract] [Full Text] [Related]

  • 4. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial.
    Stein DJ.
    Adv Ther; 2015 Jan; 32(1):57-68. PubMed ID: 25620535
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study].
    Servant D, Graziani PL, Moyse D, Parquet PJ.
    Encephale; 1998 Jan; 24(6):569-74. PubMed ID: 9949940
    [Abstract] [Full Text] [Related]

  • 6. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
    Busto UE, Naranjo CA, Bremner KE, Peachey JE, Bologa M.
    J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
    [Abstract] [Full Text] [Related]

  • 7. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR, Sramek JJ, Wardle TS, Hesselink JM, Roeschen JK.
    Psychopharmacol Bull; 1993 Jan; 29(2):303-8. PubMed ID: 7904761
    [Abstract] [Full Text] [Related]

  • 8. Clinical assessment of the safety and efficacy of lorazepam, a new benzodiazepine derivative, in the treatment of anxiety.
    Pinosky DG.
    J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):24-9. PubMed ID: 30763
    [Abstract] [Full Text] [Related]

  • 9. The effect of lorazepam on hypertension-associated anxiety: a double-blind study.
    Hart WL, Parmley LF.
    J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):41-5. PubMed ID: 30767
    [Abstract] [Full Text] [Related]

  • 10. A clinical assessment of lorazepam in the treatment of anxiety associated with gastrointestinal symptomatology.
    Berkowitz JM.
    J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):46-52. PubMed ID: 30768
    [Abstract] [Full Text] [Related]

  • 11. Lorazepam and diazepam in the treatment of neurotic anxiety: a double-blind trial.
    Valarino F, Perez-Lopez R.
    Dis Nerv Syst; 1976 Feb; 37(2):58-61. PubMed ID: 1213
    [Abstract] [Full Text] [Related]

  • 12. Lorazepam in anxiety associated with chronic enteritis and ulcerative colitis.
    Stokes DK.
    J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):53-7. PubMed ID: 30769
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam.
    Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, García-Valencia CE, Tortoriello J.
    Planta Med; 2007 Jul; 73(8):713-7. PubMed ID: 17562493
    [Abstract] [Full Text] [Related]

  • 14. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
    Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T.
    J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 16. A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety.
    Diamond BI, Nguyen H, O'Neal E, Ochs R, Kaffeman M, Borison RL.
    Psychopharmacol Bull; 1991 Nov; 27(1):67-71. PubMed ID: 1677774
    [Abstract] [Full Text] [Related]

  • 17. [New anxiolytic drugs: methodological issues].
    Ginestet D, Corruble E.
    Encephale; 1993 Nov; 19(6):627-37. PubMed ID: 12404782
    [Abstract] [Full Text] [Related]

  • 18. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
    Cohn JB, Wilcox CS.
    J Clin Psychiatry; 1986 Aug; 47(8):409-12. PubMed ID: 2874128
    [Abstract] [Full Text] [Related]

  • 19. Alpidem, a novel anxiolytic drug. A double-blind, placebo-controlled study in anxious outpatients.
    Bassi S, Albizzati MG, Ferrarese C, Frattola L, Cesana B, Piolti R, Farolfi A.
    Clin Neuropharmacol; 1989 Feb; 12(1):67-74. PubMed ID: 2565767
    [Abstract] [Full Text] [Related]

  • 20. Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.
    Minervini MG, Priore P, Farolfi A, Cesana B, Morselli PL.
    Pharmacopsychiatry; 1990 Mar; 23(2):102-6. PubMed ID: 1971117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.